Eunyong Ahn

Eunyong Ahn

Auto-generated profile, based on publicly available information

Eunyong Ahn

Research Group, Foretell My Health Pohang Republic of Korea

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SPSeung Joon Park
Seung Joon Park
HYHee Chan Yoo
Hee Chan Yoo
EAEunyong Ahn
Eunyong Ahn
ELEnzhi Luo
Enzhi Luo
YKYeabeen Kim
Yeabeen Kim
JHJung Min Han
Jung Min Han
Pancreatic ductal adenocarcinoma (PDAC) exhibits severe hypoxia, which is associated with chemoresistance and worse patient outcome. It has been reported that hypoxia induces metabolic reprogramming in cancer cells. However, it is not well known whether metabolic reprogramming contributes to hypoxia. Here, we established that increased glutamine catabolism is a fundamental mechanism inducing hypoxia, and thus chemoresistance, in PDAC cells. An extracellular matrix component–based in vitro three-dimensional cell printing model with patient-derived PDAC cells that recapitulate the hypoxic status in PDAC tumors showed that chemoresistant PDAC cells exhibit markedly enhanced glutamine catabolism compared with chemoresponsive PDAC cells. The augmented glutamine metabolic flux increased the oxygen consumption rate via mitochondrial oxidative phosphorylation (OXPHOS), promoting hypoxia and hypoxia-induced chemoresistance. Targeting glutaminolysis relieved hypoxia and improved chemotherapy efficacy in vitro and in vivo. This work suggests that targeting the glutaminolysis–OXPHOS–hypoxia axis is a novel therapeutic target for treating patients with chemoresistant PDAC. Significance: Increased glutaminolysis induces hypoxia via oxidative phosphorylation-mediated oxygen consumption and drives chemoresistance in pancreatic cancer, revealing a potential therapeutic strategy of combining glutaminolysis inhibition and chemotherapy to overcome resistance.

24 July 2023 in Nature Aging
Verified
Journal Article
Closed access
PDF file
HHHye-Sook Han
Hye-Sook Han
EAEunyong Ahn
Eunyong Ahn
EPEun Seo Park
Eun Seo Park
THTom Huh
Tom Huh
SCSeri Choi
Seri Choi
SKSeung-Hoi Koo
Seung-Hoi Koo

7 March 2026 in International Journal of Cancer
Verified
Journal Article
Open access
Whi-An KwonWhi-An Kwon
Whi-An Kwon
MLMIN KYUNG LEE
MIN KYUNG LEE
EAEunyong Ahn
Eunyong Ahn
HKHeeyeon Kim
Heeyeon Kim
Yong Sang SongYong Sang Song
Yong Sang Song
TATaejin Ahn
Taejin Ahn
Tumor‐educated platelets (TEPs) are emerging as a compelling frontier in liquid biopsy, functioning as dynamic, systemic sensors that sequester and process tumor‐derived biomolecules. This interaction imprints an integrated molecular signature of malignancy—spanning the transcriptome, proteome, lipidome, and crucially, the captured genome—within the circulating platelet population. Recent mechanistic evidence suggests that platelets can sequester extracellular DNA, including circulating tumor DNA (ctDNA), and may thereby act as a relatively protected, time‐integrated reservoir that extends the biological persistence of tumor‐derived fragments beyond the short plasma half‐life (tens of minutes to a few hours). This emerging platelet‐sequestered DNA (pDNA) signal complements more established platelet transcriptomic data; to date, most TEP‐based molecular profiling has relied on RNA and has shown promising performance in identifying diverse solid malignancies, including premalignant lesions, and in some settings facilitating localization of the tissue of origin. However, the translation of these findings into clinical‐grade assays is obstructed by substantial hurdles. Pre‐analytical inconsistencies (e.g., leukocyte/erythrocyte contamination, isolation protocol choice) introduce technical noise and pervasive batch effects that compromise reproducibility. These vulnerabilities have been underscored by failed external validations and poor generalizability of discovery‐phase classifiers in independent cohorts and prospective settings. This review critically dissects the factors influencing TEP diagnostic performance and outlines a concrete roadmap for clinical translation. We argue that rigorous standardization—universal standard operating procedures, harmonized pre‐analytics, and quantitative quality‐control metrics—is the sine qua non for implementation, to be followed by large‐scale, prospective validation trials designed to demonstrate clinical utility and by multi‐omics integration to maximize diagnostic yield.

7 September 2024 in Clinical and Translational Medicine
Verified
Journal Article
Open access
SKSe Ik Kim
Se Ik Kim
SPSangick Park
Sangick Park
EAEunyong Ahn
Eunyong Ahn
JKJeunhui Kim
Jeunhui Kim
HJHyunA Jo
HyunA Jo
Yong Sang SongYong Sang Song
Yong Sang Song

24 March 2025 in iScience
Verified
Journal Article
Open access
EAEunyong Ahn
Eunyong Ahn
SKSe Ik Kim
Se Ik Kim
SPSungmin Park
Sungmin Park
SKSarah Kim
Sarah Kim
HLHyejin Lee
Hyejin Lee
Yong Sang SongYong Sang Song
Yong Sang Song
Early detection of ovarian cancer is crucial for successful treatment, yet most cases are diagnosed at advanced stages due to a lack of effective screening. Recent advancements in RNA technology from platelets aid in early tumor detection. Here, we proposed our two-step method for assessing the existence of pelvic mass either located at ovaries or uterus with more than 99% specificity by utilizing exon-exon junction features with a sampling invariant normalization technique; then next our model finds the malignancy of detected mass with more than 99% negative predictive value for ovarian cancer to practically assist clinicians’ further investigation via combined features of exon-exon junctions, and hematology parameters. We diverged from traditional methods by employing intron-spanning reads (ISR) counts rather than gene expression levels to use splice junctions as features in our models. If integrated with current screening methods, our algorithm holds promise for identifying ovarian or endometrial cancer in its early stages.